<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086671</url>
  </required_header>
  <id_info>
    <org_study_id>M03-654</org_study_id>
    <nct_id>NCT00086671</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)</brief_title>
  <official_title>A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to study the safety and effectiveness of ABT-874 administered
      weekly or every other week in patients with relapsing remitting and secondary progressive
      multiple sclerosis as compared to placebo. Effectiveness will be measured based on MRI scans
      done periodically throughout the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was done in subjects with relapsing remitting MS or secondary progressive MS with
      the objective of assessing the safety and efficacy of 200 mg of ABT-874 weekly or QOW versus
      placebo. There were 3 phases to the study, 24 week double blind followed by 24 weeks of an
      active extension, followed by 48 weeks of double blind active extension. The trial was
      discontinued by Abbott in Aug 2006.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the cumulative number of Gd enhanced (T1 weighted) lesions during the treatment phase</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and clinical laboratory parameters</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging endpoints</measure>
    <time_frame>Screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging endpoints</measure>
    <time_frame>Baseline (Week 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging endpoints</measure>
    <time_frame>Every 4 weeks after baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging endpoints</measure>
    <time_frame>Every 12 weeks from Week 26 to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging endpoints</measure>
    <time_frame>Early Termination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ABT-874 200 mg weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT 874 QOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-874/Human monoclonal antibody against IL-12</intervention_name>
    <arm_group_label>ABT-874 200 mg weekly</arm_group_label>
    <arm_group_label>ABT 874 QOW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 55 years

          -  Diagnosis of active relapse within 12 months of screening.

          -  At least one relapse within 12 months of screening.

          -  Must be able to walk at least 65 feet with or without assistance

          -  Off Copaxone or interferon therapy for two months prior to screening

          -  Able and willing to learn to self-administer weekly injections, or have a designee who
             will administer study medication

          -  Female participants must use contraceptives while on study drug

        Exclusion Criteria:

          -  Primary progressive multiple sclerosis (PPMS)

          -  Immunosuppressive therapy (such as azathioprine, methotrexate (MTX), but excluding
             corticosteroids) within six months of randomization. Subjects with previous treatment
             with cyclophosphamide, total lymphoid irradiation, mitoxantrone, cladribine, or bone
             marrow transplantation, regardless of duration, will be excluded from participation in
             this study

          -  Systemic corticosteroid therapy within four weeks prior to the first screening
             Magnetic Resonance Imaging (MRI)

          -  Participation in any clinical study, whether or not it involves an investigational
             drug within three months prior to the screening visit

          -  Use of any investigational drug with disease-modifying potential for the treatment of
             multiple sclerosis (MS) within six months of randomization (prior use of
             investigational agents for the symptomatic treatment of MS, e.g., 4-aminopyridine
             (4-AP), may be allowed following discussion with medical monitor

          -  Concomitant statin use in doses exceeding the manufacturers' maximum recommended daily
             dosages for treatment of hypercholesterolemia or as part of an MS disease-modifying
             protocol

          -  Infection or risk factors for severe infections

          -  Excessive immunosuppression or other factors associated with it, including human
             immunodeficiency virus (HIV) infection

          -  Severe, recurrent, or persistent infections [such as Hepatitis B or C, or borreliosis
             or recurrent urinary tract infection (UTI) (&gt; 3 UTIs requiring antibiotic treatment
             per year) or recurrent pneumonia (&gt; 2 pneumonias requiring antibiotic treatment per
             year) or infected decubitus ulcers]

          -  Evidence of current inactive tuberculosis (TB) infection; recent exposure to
             mycobacterium tuberculosis (converters to a positive purified protein derivative
             [PPD]). Subjects with a positive PPD or a chest X-ray suggestive of prior TB infection
             will be excluded

          -  Active tuberculosis disease

          -  Active chronic Lyme disease

          -  Active syphilis

          -  Any other significant infection requiring hospitalization or intravenous (IV)
             antibiotics in the month prior to Screening; or

          -  Infection requiring treatment with antibiotics in the two weeks prior to Screening.

          -  Any of the following risk factors for development of malignancy:

               -  History of lymphoma or leukemia

               -  Cutaneous squamous-cell or basal cell carcinoma (EXCEPT if treated more that two
                  years prior to Screening with evidence of recurrence or residual disease)

               -  Other malignancy (EXCEPT if treated more than five years prior to Screening
                  without evidence of recurrence or residual disease) or

               -  Disease associated with an increased risk of malignancy (such as familial
                  polyposis).

          -  History of major immunologic reaction (such as serum sickness or anaphylactoid
             reaction) to an Immunoglobulin G (IgG) containing agent (such as intravenous (IV)
             gamma globulin, a fusion protein, or monoclonal antibody)

          -  Confounders of the assessment of neurologic response including other diseases that
             produce chronic neurologic manifestations (such as amyotrophic lateral sclerosis,
             Guillain-Barre syndrome, Lyme disease, myasthenia gravis, etc.)

          -  Prior exposure to anti-IL-12 antibodies

          -  Confounders of safety assessment, such as an unstable medical condition not related to
             MS (including those requiring an adjustment of treatment in the four weeks prior to
             Screening)

          -  Exacerbation of asthma requiring hospitalization in the ten years prior to Screening
             (subjects with asthma not requiring hospitalization should be discussed with the
             medical monitor prior to Screening)

          -  Pregnant or lactating females

          -  The following exclusionary laboratory values at screening or baseline:

               -  Hemoglobin (Hgb) &lt;10 g/dL in females or &lt;12 g/dL in males;

               -  White blood cell (WBC) count &lt;3 x 109/L;

               -  Platelet count &lt;100 x 109/L

               -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) x 3 upper limits
                  of normal (ULN);

               -  Serum total bilirubin &gt;/= 3 mg/dL (&gt;/= 51 x mol/L)

               -  Serum creatinine &gt;1.6 mg/dL (&gt; 141 x mol/L)

          -  Subject has a recent history of substance abuse or psychiatric illness that could
             preclude compliance with the protocol

          -  In the eight weeks prior to study drug administration, the subject has received a
             transfusion of any blood product, or has had 500 mL or more of blood removed by
             repetitive or one-time blood donation, plasmapheresis, or plasma exchange, or has lost
             550 mL or more blood because of hemorrhage; or

          -  For any reason, subject is considered by the investigator to be an unsuitable
             candidate to receive ABT-874.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Kaul, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 107</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 163</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 156</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 161</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 84</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 111</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 108</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 109</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 258</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 261</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 158</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 259</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 110</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 113</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 114</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132</name>
      <address>
        <city>Greenfield Park</city>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 82</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 169</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134</name>
      <address>
        <city>Vancouver</city>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138</name>
      <address>
        <city>Nijmwegen</city>
        <zip>6533 PA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139</name>
      <address>
        <city>Sittard</city>
        <zip>6131 BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 159</name>
      <address>
        <city>Liverpool</city>
        <zip>L97LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140</name>
      <address>
        <city>London</city>
        <zip>SE1 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 142</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144</name>
      <address>
        <city>Oxford</city>
        <zip>OX2 6HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 143</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160</name>
      <address>
        <city>Whitechapel</city>
        <zip>E1 1 BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2004</study_first_submitted>
  <study_first_submitted_qc>July 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2004</study_first_posted>
  <disposition_first_submitted>August 24, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 24, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 29, 2011</disposition_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

